Results 1 to 10 of about 42,124 (246)

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer

EMBO Molecular Medicine, 2019
Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains ...
Liping Ye, Chuyong Lin, Xi Wang, Qiji Li, Yue Li, Meng Wang, Zekun Zhao, Xianqiu Wu, Dongni Shi, Yunyun Xiao, Liangliang Ren, Yunting Jian, Meisongzhu Yang, Ruizhang Ou, Guangzheng Deng, Ying Ouyang, Xiangfu Chen, Jun Li, Libing Song   +18 more
doaj   +3 more sources

MIR497HG‐Derived miR‐195 and miR‐497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer [PDF]

Advanced Science, 2023
Tamoxifen is commonly used for the treatment of patients with estrogen receptor‐positive (ER+) breast cancer, but the acquired resistance to tamoxifen presents a critical challenge of breast cancer therapeutics.
Yao Tian, Zhao‐Hui Chen, Peng Wu, Di Zhang, Yue Ma, Xiao‐Feng Liu, Xin Wang, Dan Ding, Xu‐Chen Cao, Yue Yu   +9 more
doaj   +3 more sources

Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer

Frontiers in Pharmacology, 2020
Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism
Jingwei Yao, Jingwei Yao, Kun Deng, Jialu Huang, Ruimin Zeng, Jianhong Zuo, Jianhong Zuo, Jianhong Zuo   +7 more
doaj   +3 more sources

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation

Molecular Therapy: Oncolytics, 2020
Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER)-positive breast cancer.
Jun Zhou, Kehao Le, Ming Xu, Jie Ming, Wen Yang, Qiulei Zhang, Linlin Lu, Zihan Xi, Shengnan Ruan, Tao Huang   +9 more
doaj   +3 more sources

PARP14-mediated glycolysis enhances Tamoxifen resistance in estrogen receptor + breast cancer cells [PDF]

Discover Oncology
Background Resistance to Tamoxifen is a major challenge in the therapeutic management of estrogen receptor (ER) + breast cancer (BC). Glycolysis, as reported, exerts a crucial influence on the regulation of Tamoxifen resistance in BC, highlighting the ...
Wenju Mo, Fanrong Zhang, Chen Wang, Xiaowen Ding, Lili Ren   +4 more
doaj   +2 more sources

Tamoxifen: Mechanisms of Resistance

, 2017
The role of estrogen in breast cancer has been recognized for decades. The selective estrogen receptor modulator tamoxifen was the first targeted therapy for the treatment of breast cancer. It was also the first drug approved by the FDA for the reduction
Adams, Cyrus McCoy
openaire   +3 more sources

Tamoxifen Resistance in Breast Cancer

Drugs, 2001
Tamoxifen has been used for the systemic treatment of patients with breast cancer for nearly three decades. Treatment success is primarily dependent on the presence of the estrogen receptor (ER) in the breast carcinoma. While about half of patients with advanced ER-positive disease immediately fail to respond to tamoxifen, in the responding patients ...
Dorssers, L.C.J., Flier, S. van der, Brinkmann, A.O., Agthoven, T. van, Veldscholte, J., Berns, E.M.J.J., Klijn, J.G.M., Beex, L.V.A.M., Foekens, J.A.   +8 more
openaire   +5 more sources

Molecular Analysis of Acquired Tamoxifen Resistance in Breast Cancer Cell Line

Asian Pacific Journal of Cancer Biology, 2017
Background: Tamoxifen is an FDA approved drug for the prevention and the treatment of breast cancer, but its therapeutic benefit is limited by the development of drug resistance.
Mansour Abachi, Monir Salati, Shahram Araghi, Reza Shirkoohi, Ali Eslamifar   +4 more
doaj   +4 more sources

Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer

EBioMedicine, 2020
Background: Prioritization of breast cancer patients based on the risk of resistance to tamoxifen plays a significant role in personalized therapeutic planning and improving disease course and outcomes. Methods: In this work, we demonstrate that a genome-
Sarra M. Rahem, Nusrat J. Epsi, Frederick D. Coffman, Antonina Mitrofanova   +3 more
doaj   +3 more sources

Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1/miR-200a-3p/MKP1 axis-mediated apoptosis suppression [PDF]

Journal of Experimental & Clinical Cancer Research
Background Tamoxifen resistance remains a significant challenge in the endocrine therapy of estrogen receptor-positive (ER+) breast cancer. Cancer-associated fibroblasts (CAFs) facilitate therapeutic resistance through exosome secretion, yet the role of ...
Chenghui Wu, Xi Sun, Yujie Lu, Haoyu Wang, Zhengyuan Yu, Zheng Wang, Renhong Huang, Yihua Jin, Xing Chen, Haixia Xie, Yu Zong, Kunwei Shen, Min Jiang, Yujie Tang, Xiaosong Chen   +14 more
doaj   +2 more sources